DNDi, MPP speed up in hepatitis C pan-genotypic treatment access


A major cause of liver cancer and cirrhosis, chronic infection by hepatitis C virus (HCV) affects more than 80 million people worldwide, 85% of whom live in low (13%) and middle (72%) income countries (LMICs) [1]. Around 15% of Egypt’s population, for example, is infected – one of the world’s highest prevalence rate – while it is estimated that 12 million people in India have hepatitis C [2].

At least 1.2 million people in Japan and three million Americans suffer from hepatitis C, while in Europe the infection ranks high as a public-health challenge (between 0.4 and 3.5% of the population in different EU Member States) and the most common single cause of liver transplantation [3–5].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment